DigestRedComo funciona
Red
/
Empresas
Ia
No verificado

Iambic Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludTécnica

15 Comunicados de prensa

Ver todos los comunicados de prensa
21/10/2025
Mercado laboral
Industria
Técnica
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Ciencia
Oncología
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
20/10/2025
Técnica
Ciencia
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Oncología
Eventos
Industria
Iambic Shares Clinical Data from Ph1/1B Study of IAM1363, a Highly Selective Type-2 HER2 Inhibitor, Demonstrating Monotherapy Activity in Heavily Pretreated Patients with HER2 Alterations, at the 2025 ESMO Congress
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
01/10/2025
Ciencia
Biotecnología
Farmacéutica
Salud
Técnica
Medicina - Varios
Mercado laboral
Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
03/09/2025
Oncología
Salud
Técnica
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Industria
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
02/09/2025
Técnica
Ciencia
Medicina - Varios
Software
Biotecnología
Salud
Farmacéutica
Eventos
Iambic to Participate in September Investor Conferences
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
05/08/2025
Multimedia
Salud
Técnica
Farmacéutica
Biotecnología
Mercado laboral
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
10/06/2025
Biotecnología
Técnica
Salud
Sanidad
Farmacéutica
Ciencia
Software
Medicina - Varios
Eventos
Iambic Named to CNBC’s 2025 Disruptor 50 List
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
04/06/2025
Eventos
Industria
Oncología
Salud
Técnica
Medicina - Varios
Farmacéutica
Biotecnología
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
28/05/2025
Salud
Técnica
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Iambic Therapeutics to Participate in June Investor Conferences
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0
06/01/2025
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Fuente
Iambic Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0